This trial will assess the tolerability, safety, pharmacokinetics, and anti-tumour activity of lomonitinib in R/R AML patients. Credit: Nemes Laszlo / Shutterstock.com.

Eilean Therapeutics has received approval from the Human Research Ethics Committee (HREC) in Australia to commence a Phase I clinical trial of its drug candidate lomonitinib (ZE46-0134) for acute myeloid leukaemia (AML).

This trial is set to assess the tolerability, safety, pharmacokinetics, and anti-tumour activity of lomonitinib when used as a single agent in patients with relapsed/refractory AML (r/r AML) who have FLT3 mutations.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

It will have a dose escalation followed by an expansion phase and will enrol up to 60 participants.

The trial is scheduled to commence in the second quarter of this year, with multiple investigative sites across Australia participating.

Lomonitinib is a selective plan-FLT3/IRAK4 inhibitor designed to target FLT3 mutations prevalent in AML and potential escape pathways.

See Also:

FLT3 mutations are the most common mutations found in AML patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Resistance to FLT3 inhibitors typically arises through two main mechanisms: the FLT3-ITD-F691L mutation, known as the ‘gatekeeper’ mutation, and the activation of the IRAK4 pathway. Lomonitinib has been developed to inhibit both these resistance mechanisms.

Eilean’s strategy focuses on discovering and developing small molecule inhibitors that act on escape mutations in various cancers.

The company employs hybrid AI from Expert Systems, which utilises data, chemical and biological tools, and expertise to speed up the discovery and optimisation of various therapies.

Eilean Therapeutics CEO Iain Dukes said: “This is a major milestone for the Eilean team, as we continue to progress an accelerated development of lomonitinib.

“Given the safety profile, extended half-life and target engagement demonstrated in a healthy volunteer study, we look forward to initiating our clinical trial and testing our approach in r/r AML patients.”